mProX™ Human TNFRSF14 Stable Cell Line

Product Information

Target Family

Oncology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;T24;EJ

Target Classification

Oncology Cell Lines

Target Research Area

Infectious Research

Related Diseases

Herpes Simplex; Ezb Diffuse Large B-Cell Lymphoma

Gene ID

Human:8764

UniProt ID

Human:Q92956

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF14, also known as HVEM (herpesvirus entry mediator), plays a pivotal role in the modulation of immune responses. Recent studies have highlighted its significance in the context of immune checkpoint pathways. Specifically, TNFRSF14 has been identified as a potential therapeutic target for enhancing antitumor immunity. Its interaction with BTLA, a co-inhibitory receptor, has been shown to regulate T cell responses, making it a focal point in cancer immunotherapy research. Furthermore, the modulation of TNFRSF14 can influence the balance between stimulatory and inhibitory signals in the immune system, offering avenues for therapeutic interventions in various diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human TNFRSF14 Stable Cell Line (S01YF-1023-PY240). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Peyton Johnson (Verified Customer)

What is the significance of TNFRSF14 in rheumatoid arthritis susceptibility? Sep 01 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF14 polymorphisms, in combination with other genetic factors, can determine susceptibility to rheumatoid arthritis, highlighting its role in the genetic background of the disease. Sep 01 2020

chat Skyler Smith (Verified Customer)

How does TNFRSF14 contribute to breast cancer prognosis? Sep 09 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF14, along with other pyroptosis-related risk genes, can be used to evaluate prognosis and immune infiltration in breast cancer, suggesting its role as a tumor suppressor gene. Sep 09 2020

Published Data

Fig.1 The TNFRSF14 vector was transfected into T24 cells, and subsequent Western blot analysis was performed. Furthermore, si-TNFRSF14 was transfected into EJ-M3 cells, and Western blot analysis was conducted 72 hours post-transfection.

The quantification of band intensity and protein expression normalization against GAPDH were carried out in T24 cells 72 h after transfection with the TNFRSF14 vector, along with Western blot analysis of AKT, p-AKT, P70, and caspase3-p17. The means ± standard deviation were presented in the data, and significance (*P<0.05 vs. NC) was observed. Similar analyses were performed in EJ-M3 cells 72 h after transfection with si-TNFRSF14, with band intensity quantification and GAPDH-normalized protein expression levels. Significance was noted (*P<0.05, **P<0.01 vs. NC). The terms used in the study included AKT (protein kinase B), NC (negative control), p- (phosphorylated-), P70 (P70 S6 kinase), and TNFRSF14 (tumor necrosis factor receptor superfamily member 14).

Ref: Zhu, Yu‑Di, and Ming‑Yue Lu. "Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis." Molecular medicine reports 18.3 (2018): 3403-3410.

Pubmed: 30066919

DOI: 10.3892/mmr.2018.9306

Research Highlights

Chen, Yan. et al. "HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma." PeerJ, 2023.
The HtrA family of serine proteases plays a crucial role in various malignancies due to dysregulation. Despite this, there is limited research on the involvement of HtrAs in head and neck squamous cell carcinoma (HNSCC). This study aims to examine the expression, prognostic significance, and functional importance of HtrAs in HNSCC. Results may provide a better understanding of HtrAs in HNSCC progression and may potentially serve as a therapeutic target for the disease.
Chen, Yan. et al. "HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma." PeerJ, 2023.
Pubmed: 37842043 DOI: 10.7717/peerj.16237

K McFarlin, Brian. et al. "Dry blood spot samples to monitor immune-associated mRNA expression in intervention studies: Impact of Baker's yeast beta glucan." Methods (San Diego, Calif.), 2023.
In a field setting, monitoring the immunological response to physical stressors can be difficult as current methods require a laboratory visit and venipuncture blood collection. This study aimed to determine the feasibility of using a dry blood spot (DBS) method to measure total RNA and assess the impact of supplementing with Baker's Yeast Beta Glucan (BYBG; Wellmune; 250 mg/d) on post-exercise mRNA expression. Participants in a 90 min run/walk trial in a hot, humid environment provided venous DBS samples before (PRE), immediately after (POST), 2 (2H), and 4 (4H) hours. Results from the 574-plex Human Immunology mRNA panel (Nanostring) revealed that BYBG supplementation was associated with the altered expression of 12 mRNAs, with an increase in 11 immune-response pathways. These findings suggest that DBS samples can provide valuable information on mRNA biomarkers in intervention studies. BYBG supplementation may support immunity, reduce susceptibility to infection, and improve post-exercise recovery. Further research could explore the use of DBS sampling for other nutritional or medical interventions.
K McFarlin, Brian. et al. "Dry blood spot samples to monitor immune-associated mRNA expression in intervention studies: Impact of Baker's yeast beta glucan." Methods (San Diego, Calif.), 2023.
Pubmed: 37741562 DOI: 10.1016/j.ymeth.2023.09.006